Hormonal
A 12-week carbohydrate-restricted diet (CRD) produces significantly greater improvements in metabolic syndrome markers (glucose, insulin, triglycerides, HDL-C, and adiposity) compared to a low-fat diet (LFD) in overweight subjects with atherogenic dyslipidemia, despite similar caloric intake.
If you have metabolic syndrome markers (high triglycerides, low HDL, insulin resistance), switching to a low-carbohydrate diet (around 12% carbs) for 12 weeks can significantly improve your blood sugar, insulin levels, and fat profile better than a standard low-fat diet, even if you don't strictly count calories. Focus on restricting carbohydrates rather than just fat.
Both interventions led to improvements in several metabolic markers, but subjects following the CRD had consistently reduced glucose (-12%) and insulin (-50%), insulin sensitivity (-55%), weight loss (-10%), decreased adiposity (-14%), and more favorable triacylglycerol (TAG) (-51%), HDL-C (13%) and total cholesterol/HDL-C ratio (-14%) responses.
Why this rating
Randomized controlled trial with 40 subjects, clear inclusion criteria (atherogenic dyslipidemia), and robust statistical analysis, though limited by short duration (12 weeks) and small sample size.
Source
Carbohydrate Restriction has a More Favorable Impact on the Metabolic Syndrome than a Low Fat Diet
Jeff S. Volek et al. · Lipids · 2008
DOI 10.1007/s11745-008-3274-2
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →